Legislation - SB0987

Title: Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising
Sponsored by: Senator Lewis Young
Status: In the Senate - Hearing 3/11 at 1:00 p.m.
Analysis: Fiscal and Policy Note

Synopsis

Providing an addition modification under the corporate income tax for the amount of certain direct-to-consumer advertising expenses for certain covered drugs paid or incurred during the taxable year that are deducted under the Internal Revenue Code; providing for the distribution of revenue attributable to the addition modification; etc.

Committees

Original:: Budget and Taxation Click to view Recorded Media

Details

Bill File Type: Regular

Effective Date(s): July 1, 2026

History

Legislation History
Chamber Senate Calendar Date 2/15/2026 Legislative Date 2/15/2026 Action First Reading Senate Rules Proceedings
Chamber Calendar Date Legislative Date Action Text - First - Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising Proceedings
Chamber Senate Calendar Date 3/04/2026 Legislative Date 3/05/2026 Action Rereferred to Budget and Taxation Proceedings
Chamber Senate Calendar Date 3/05/2026 Legislative Date 3/05/2026 Action Hearing 3/11 at 1:00 p.m. Proceedings

Chamber	Calendar Date	Legislative Date	Action
Senate	2/15/2026	2/15/2026	First Reading Senate Rules
			Text - First - Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising
Senate	3/04/2026	3/05/2026	Rereferred to Budget and Taxation
Senate	3/05/2026	3/05/2026	Hearing 3/11 at 1:00 p.m.

File Code

Subjects

Statutes